Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome

Metabolism: Clinical and Experimental

Volumn 57, Issue 9, 2008, Pages 1278-1285

  Uchida, Toshihiko ^a   Shimizu, Minoru ^a   Sakai, Yoshihiko ^a   Nakano, Tomoki ^a   Hara, Kenji ^a   Takebayashi, Kohzo ^a   Inoue, Teruo ^b   Node, Koichi ^b   Inukai, Toshihiko ^a   Takayanagi, Kan ^a   Aso, Yoshimasa ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; LOSARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; TREATMENT DURATION;

ADIPONECTIN; AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOLECULAR WEIGHT; OSMOLAR CONCENTRATION; TIME FACTORS;

EID: 48949083990     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.04.024     Document Type: Article

References (42)

1. Kannel W.B., Wilson P.W., and Zhang T.J. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 121 (1991) 1268-1273
2. Lind L., Berne C., and Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 13 (1995) 1457-1462
3. Segura J., Campo C., Ruilope L.M., and Rodicio J.L. Do we need to target 'prediabetic' hypertensive patients?. J Hypertens 23 (2005) 2119-2125
4. Sharma A.M. Is there a rationale for angiotensin blockade in the management of obesity hypertension?. Hypertension 44 (2004) 12-19
5. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H., Wachtell K., Dahlof B., et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20 (2002) 1879-1886
6. Kjeldsen S.E., Julius S., Mancia G., McInnes G.T., Hua T., Weber M.A., et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2 (2006) 1405-1412
7. Burnier M., and Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24 (2006) 11-25
8. Folli F., Kahn C.R., Hansen H., Bouchie J.L., and Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100 (1997) 2158-2169
9. Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
10. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
11. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
12. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
13. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
14. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
15. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
16. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
17. Schraw T., Wang Z.V., Halberg N., Hawkins M., and Scherer P.E. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology (2008) [Epub ahead of print]
18. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279 (2004) 12152-12162
19. Nakano Y., Tajima S., Yoshimi A., Akiyama H., Tsushima M., Tanioka T., et al. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 47 (2006) 1572-1582
20. Aso Y., Yamamoto R., Wakabayashi S., Uchida T., Takayanagi K., Takebayashi K., et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55 (2006) 1954-1960
21. Aso Y., Yamamoto R., Suetusgu M., Matsumoto S., Wakabayashi S., Matsutomo R., et al. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with type 2 diabetes. Diabet Med 24 (2007) 962-968
22. Schupp M., Lee L.D., Frost N., Umbreen S., Schmidt B., Unger T., et al. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 47 (2006) 586-589
23. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
25. Diez J. Review of the molecular pharmacology of losartan and its possible relevance to stroke prevention in patients with hypertension. Clin Ther 28 (2006) 832-848
26. Kramer C., Sunkomat J., Witte J., Luchtefeld M., Walden M., Schmidt B., et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 90 (2002) 770-776
27. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272 (1997) 3406-3410
28. Wang Z.V., and Scherer P.E. Adiponectin, cardiovascular function, and hypertension. Hypertension 51 (2008) 8-14
29. Zandbergen A.A., Lamberts S.W., Janssen J.A., and Bootsma A.H. Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. Eur J Endocrinol 155 (2006) 293-296
30. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
31. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C., American Heart Association, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
32. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
33. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
34. Hara K., Horikoshi M., Yamauchi T., Yago H., Miyazaki O., Ebinuma H., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29 (2006) 1357-1362
35. Appel G.B., Radhakrishnan J., Avram M.M., DeFronzo R.A., Escobar-Jimenez F., Campos M.M., et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 26 (2003) 1402-1407
36. Kannel W.B., and MacGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2 (1979) 120-126
37. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
38. Mukamal K.J., Nesto R.W., Cohen M.C., Muller J.E., Maclure M., Sherwood J.B., et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 24 (2001) 1422-1427
39. Aguilar D., Solomon S.D., Kober L., Rouleau J.L., Skali H., McMurray J.J., et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110 (2004) 1572-1578
40. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
41. Krakoff J., Funahashi T., Stehouwer C.D., Schalkwijk C.G., Tanaka S., Matsuzawa Y., et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26 (2003) 1745-1751
42. Daimon M., Oizumi T., Saitoh T., Kameda W., Hirata A., Yamaguchi H., et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 26 (2003) 2015-2020